Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Recurrence

NCT04084951 2023-04-14

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

30 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT02061761 2023-03-24

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Phase 1/2 Completed

106 enrolled 27 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT04730349 2023-03-24

PIVOT IO 020

Phase 1/2 Terminated

15 enrolled 14 charts

CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

NCT03435640 2023-03-08

REVEAL

Phase 1/2 Terminated

64 enrolled 22 charts

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Recurrence, Sarcoma, Colorectal Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03620123 2022-11-18

OPTIM

Phase 2 Completed

54 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT04913922 2022-11-08

AARON

Phase 2 Unknown

30 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03825367 2022-10-12

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Phase 1/2 Unknown

13 enrolled

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT05068609 2022-05-05

VOLUME-PRO

Completed

509 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03132038 2022-01-11

NISCAHN

Phase 2 Completed

98 enrolled

Head & Neck

Neoplasm Metastasis, Recurrence, Salivary Gland Neoplasms

NCT03023527 2018-05-23

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Phase 1 Terminated

6 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT02962804 2018-03-05

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

Phase 2 Withdrawn

Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Recurrence

NCT00441337 2015-02-20

MDX1106-01

Phase 1 Completed

39 enrolled 28 charts

DermatologicGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Prostatic Neoplasms, Recurrence, Colorectal Neoplasms

Clinical Trials

ACTengine

HESTIA

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

PRiME II

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

GlitIpNi

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

CheckMate 914

LOGICAN

Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

PIVOT IO 020

REVEAL

OPTIM

AARON

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

VOLUME-PRO

NISCAHN

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

MDX1106-01